personalized medicine

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.

Danish biotech $EVAX will announce full-year 2025 financial results and business update March 5, detailing AI-Immunology platform development across oncology, infectious disease, and autoimmune applications.

Cord blood banking market expected to grow 47% to $49.85B by 2031, driven by expanding stem cell therapies and regenerative medicine applications.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.

Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.

Human microbiome market expected to grow nearly fourfold to $3.27B by 2035, driven by advancing sequencing technology and 215+ therapeutic candidates in clinical development.

SNP genotyping market projected to grow from $8.08B (2026) to $19.48B (2034) at 11.7% annual rate, driven by personalized medicine adoption and genomic technology advances.